However, a recent study showed that across multiple cancers, responses to anti-PDL1 antibody therapy were observed in individuals expressing high levels of PDL1, especially on tumor-infiltrating lymphocytes, suggesting a functional role of PDL1 on immune cells (66). Here, CD274 is linked to cancer.